



For moderate to severe dry eye

Conserve tears for all-day relief.

Once-daily,* preservative-free LACRISERT® Extends tear life for all-day lubrication and protection

- ▶ Unlike artificial tears, LACRISERT® works continuously to stabilize and thicken tears for all-day relief¹
- ▶ LACRISERT® begins to gently dissolve and lubricate within minutes²

LACRISERT® preferred over artificial tears^{1,3}

- ▶ 78% of patients in a clinical study preferred LACRISERT® for relief of dry eye symptoms^{1,3}
- ▶ Significantly greater increase in corneal tear thickness and tear stability with LACRISERT®³

Most adverse reactions were mild and transient and included transient blurring of vision, ocular discomfort or irritation, matting or stickiness of eyelashes, photophobia, hypersensitivity, edema of the eyelids, and hyperemia. LACRISERT® is contraindicated in patients who are hypersensitive to hydroxypropyl cellulose. If improperly placed, LACRISERT® may result in corneal abrasion.

*Some patients may require the flexibility of twice-daily dosing for optimal results.¹

[†]In a 4-week, double-blind, crossover study of 32 patients with moderate to severe keratoconjunctivitis sicca.

References: **1.** LACRISERT® [package insert]. Lawrenceville, NJ: Aton Pharma, Inc.; 2007. **2.** Lamberts DW, Langston DP, Chu W. A clinical study of slow-releasing artificial tears. *Ophthalmology*. 1978;85:794-800. **3.** Katz JI, Kaufman HE, Breslin C, Katz IM. Slow-release artificial tears and the treatment of keratitis sicca. *Ophthalmology*. 1978;85:787-793.

For more information, visit www.LACRISERT.com or call 1-877-ATON-549.

Please see brief summary of Prescribing Information on adjacent page.

ATON

P H A R M A

Lawrenceville, NJ 08648, USA

Rx Only

LACRISERT® (hydroxypropyl cellulose) OPHTHALMIC INSERT

DESCRIPTION

LACRISERT® Ophthalmic Insert is a sterile, translucent, rod-shaped, water soluble, ophthalmic insert made of hydroxypropyl cellulose, for administration into the inferior cul-de-sac of the eye.

Each LACRISERT is 5 mg of hydroxypropyl cellulose. LACRISERT contains no preservatives or other ingredients. It is about 1.27 mm in diameter by about 3.5 mm long. LACRISERT is supplied in packages of 60 units, together with illustrated instructions and a special applicator for removing LACRISERT from the unit dose blister and inserting it into the eye.

INDICATIONS AND USAGE

LACRISERT is indicated in patients with moderate to severe dry eye syndromes, including keratoconjunctivitis sicca. LACRISERT is indicated especially in patients who remain symptomatic after an adequate trial of therapy with artificial tear solutions. LACRISERT is also indicated for patients with exposure keratitis, decreased corneal sensitivity, and recurrent corneal erosions.

CONTRAINDICATIONS

LACRISERT is contraindicated in patients who are hypersensitive to hydroxypropyl cellulose.

WARNINGS

Instructions for inserting and removing LACRISERT should be carefully followed.

PRECAUTIONS

General

If improperly placed, LACRISERT may result in corneal abrasion.

Information for Patients

Patients should be advised to follow the instructions for using LACRISERT which accompany the package. Because this product may produce transient blurring of vision, patients should be instructed to exercise caution when operating hazardous machinery or driving a motor vehicle.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Feeding of hydroxypropyl cellulose to rats at levels up to 5% of their diet produced no gross or histopathologic changes or other deleterious effects.

Pediatric Use

Safety and effectiveness in pediatric patients have not been established.

Geriatric Use

No overall differences in safety or effectiveness have been observed between elderly and younger patients.

ADVERSE REACTIONS

The following adverse reactions have been reported in patients treated with LACRISERT, but were in most instances mild and transient: transient blurring of vision, ocular discomfort or irritation, matting or stickiness of eyelashes, photophobia, hypersensitivity, edema of the eyelids, and hyperemia.

DOSAGE AND ADMINISTRATION

One LACRISERT ophthalmic insert in each eye once daily is usually sufficient to relieve the symptoms associated with moderate to severe dry eye syndromes. Individual patients may require more flexibility in the use of LACRISERT; some patients may require twice daily use for optimal results.

Clinical experience with LACRISERT indicates that in some patients several weeks may be required before satisfactory improvement of symptoms is achieved.

Issued June 2007